What’s new in the 2025 ELN Recommendations for CML? In a new video Professor Jane Apperley outlines the key changes and what they mean for clinical practice.
A helpful overview for anyone involved in CML care.

Watch the video and explore the full summary.

2025 ELN recommendations on the management of CML

Professor Jane Apperley

Imperial College, London (UK)

Background:
The European LeukemiaNet (ELN) has issued expert consensus recommendations for managing CML since 2006, with updates in 2009, 2013, and 2020. The 2025 version, recently accepted for publication in Leukemia, reflects evolving clinical data, new therapies, and a growing emphasis on individualised care.
Click here to access the full publication

Table of contents:

• ELN recommendations: process (00:40)
• Defining disease phase in CML - including new WHO criteria for defining disease phase in CML (04:14)
• Prognosis at diagnosis - including impact of ASXL1 mutation at diagnosis (10:58)
• Monitoring response to treatment (17:43)
• Response milestones 2025 - including 'Why personalise the milestones?' (19:08)
• First-line treatment - including first-line treatment with asciminib (31:32)
• Resistance (36:20)
• Treatment-free remission (38:14)
• Parenting - including pregnancy outcomes and planning a pregnancy in established CML (39:22)
• Adverse events (42:33)

{rscomments off}